secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001104659-23-030103
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.08, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics schedules Type C FDA meeting for IV Tramadol; appoints MacLean to board, Kranzler Chairman
--------------------------------------------------------------------------------

- Type C FDA meeting on March 9, 2023 to discuss IV Tramadol respiratory depression study protocol; update expected April 2023.
- Board expanded to six; CEO Alexandra MacLean appointed director; Jay Kranzler named Chairman, Lindsay Rosenwald remains director.
- Annual meeting set for June 22, 2023; record date April 25, 2023; stockholder proposal deadline March 24, 2023.
- FDA previously agreed on study design aspects in August 2022 Type A meeting for IV Tramadol.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/0001104659-23-030103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923030103/tm238871d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-030103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer